期刊文献+

戈谢病与帕金森病研究进展 被引量:3

Progress in Gaucher Disease and Parkinson's Disease
下载PDF
导出
摘要 帕金森病是一种常见的老年神经系统变性疾病,最新的研究发现,帕金森病与少见的遗传病戈谢病有关。戈谢病患者帕金森病的临床特征,多数发病年龄早,无明显的静止性震颤,对左旋多巴的反应差,也有典型的左旋多巴有反应的帕金森病。葡萄糖脑苷脂酶基因突变,即使是杂合子也有发展为帕金森病的危险,而且帕金森病患者葡萄糖脑苷脂酶基因突变比普通人群高。在戈谢病合并帕金森病患者病理研究中发现共核蛋白阳性的路易体和包涵体。 Parkinson disease is a co,non neurodegenerative disease in eider. The newest finding showed that this disease is related to gancher, which is a rare genetic disorder. The clinical manifestation of parkinsonism in patients with Gaucher disease is characterized by early-onset, no tremor and poor response to levodopa therapy, but some present signs of typical Parkinson disease and a favorable response to levodopa therapy. Gaucher also has the type of parkinson's disease reacting to levodopa. Glucocerebi'osidase gene mutations,even in heterozygotes, may be a risk factor for development of parkinsonism, and the mutations in patientd with parkinsonism are more often than expected in general population. Synuclein-positive Lewy bodies and inclusions has been found in pathological study of patients with gaucher and parkinson's disease.
出处 《医学综述》 2008年第4期583-585,共3页 Medical Recapitulate
关键词 帕金森病 戈谢病 遗传 Parkinson's disease Gaucher disease Genetics
  • 相关文献

参考文献16

  • 1Tayebi N,Walker J,Stubblefield B,et al.Gaucher disease with parkinsonian manifestations:dose glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?[J].Mol Genet Metab,2003,79(2):104-109.
  • 2Bembi B,Zambito Marsala S,Sidransky E,et al.Gaucher's disease with Parkinson's disease:clinical and pathological aspects[J].Neurology,2003,61(1):99-101.
  • 3Itokawa K,Tamura N,Kawai N,et al.Parkinsomsm in type 1 Gaucher's disease[J].Intern Med,2006,45(20):1165-1167.
  • 4Goker-Alpan O,Schiffmann R,LaMarca ME,et al.Parkinsonism among Gaucher disease carriers[J].J Med Genet,2004,41(12):937-940.
  • 5Lwin A,Orvisky E,Goker-Alpan O,et al.Glucocerebrosidase mutations in subjects with parkinsonism[J].Mol Genet Metab,2004,81(1):70-73.
  • 6Aharon-Peretz J,badarny S,Rosenbaum H,et al.Mutations in the glucocerebrosidase gene and Parkinson disease:phenotype-genotype correlation[J].Neurology,2005,65(9):1460-1461.
  • 7clark LN,Nicolai A,Afridi S,et al.Pilot association study of the β-glucocerebrosidase N370S allele and Parkinson's disease in subjects of jewish ethnicity[J].Mov Disord,2005,20(1):100-103.
  • 8Sato C,Morgan A,Lang AE,et al.Analysis of the glucocerebrosidase gene in Parkinson's disease[J].Mov Disord,2005,20(3):367-370.
  • 9Eblan MJ, Nguyen J, Ziegler SG, et al. Glucocerebrosidase mutations are also found in subjects with early-onset parkinsonism from Venezuela [ J]. Mov Disord, 2006,21 (2) : 282-283.
  • 10Wong K, Sidransky E, Verma A, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease[J]. Mol Genet Metab,2004,82 (3) : 192-207.

同被引文献28

  • 1Brady RO, Kanfer JN, Shapiro D. Metabolism of glucocerebrosides, Ⅱ: evidence of art enzymatic deficiency in Gaucher's disease[J]. Biochem. Biophys. Res. Commun, 1965, 18:221-225.
  • 2Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modem management [J]. Br J Haerntol. 2005, 129 (2) : 178 - 188.
  • 3Beutler E, Nguyen N J, Henneberger MW, et al. Gaucher disease: gene frequencies in the Ashkenazi Jewish population[J]. Am J Hum Genet. 1993,52(1):85-88.
  • 4Hoffbrand AV, Pettit JE, eds. Lysosomal storage diseases. Color Atlas of Clinical Hematology[M]. 3rd ed. In: St Louis, Mo, Mosby,2000,303 - 307.
  • 5Chen M, Wang J. Gaucher disease: review of the literature[J]. Arch Pathol Lab Med,2008,132(5) :851 - 853.
  • 6Elstein D, Abrahamov A, Hadas Halpern I, et al. Gaucher' s disease[J]. Lancet,2001,358(9278) :324-327.
  • 7Aerts JM, Hollak CE. Plasma and metabolic abnormalities in Gaucher' s disease[J]. Baillieres Clin Haematol. 1997,10 (4) :691-709.
  • 8Terk MR, Dardashti S, Liebman HA. Bone marrow response in treated patients with Gaucher disease: evaluation by T1 - weighted magnetic resonance images and correlation with reduction in liver and spleen volume [ J ]. Skeletal Radiol, 2000, 29 ( 10 ) : 563 571.
  • 9Brady RO. Enzyme replacement for lysosomal diseases[J]. Ann Rev Med, 2006,57 : 283 - 296.
  • 10Lable approved on 02/26/2010 for VPRIVTM , NDA no. 022575 [ EB/OL ]. [ 2010 - 02 - 26 ] http ://www. accessdata, fda. gov/ drugsatfda_docs/label/2010/022575 lbl. pdf.

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部